CTSB and neoplasm: The ADC presented here allows the progressive amplification of drug release, which is linked to the antibody via a cleavable dipeptide linker, presumably upon being metabolised by appropriate proteases (e.g. cathepsin B), which are released into the surrounding tissue upon induction of tumour cell death.